ChromaDex continues to drive innovation and
growth with its proprietary Tru Niagen® supplement, backed by
strong financial performance and a robust intellectual property
portfolio
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+) research with a focus on
healthy aging, today announced its inclusion in the Russell 2000®
Index as part of the annual reconstitution of the Russell stock
indexes. This inclusion will be effective at the opening of U.S.
equity markets on Monday, July 1, 2024, based on the preliminary
list of additions posted on Friday, May 24, 2024.
Rob Fried, CEO of ChromaDex and Founder of Tru Niagen commented,
"Joining the Russell 2000 Index reflects our sustained growth and
leadership in NAD+ research. Tru Niagen® is the gold standard NAD+
supplement, backed by scientific rigor, the highest quality
standards, and a robust intellectual property portfolio. This
achievement underscores our commitment to driving long-term value
for our shareholders as we expand our global footprint, innovate
with new products, and advance the science of healthy aging."
The annual Russell indexes reconstitution captures the 4,000
largest U.S. stocks as of Friday, June 28, 2024, ranking them by
total market capitalization. Membership in the U.S. all-cap Russell
3000® Index, which lasts for one year, guarantees automatic
inclusion in either the large-cap Russell 1000® Index or the
small-cap Russell 2000® Index, along with the appropriate growth
and value style indexes. FTSE Russell primarily determines index
membership based on objective market-capitalization rankings and
style attributes.
The ChromaDex team, comprised of world-renowned scientists,
works with independent investigators from esteemed universities and
research institutions around the globe to uncover the full
potential of NAD+. A vital coenzyme found in every cell of the
human body, NAD+ declines with age and exposure to other everyday
stressors, which contributes to age-related changes in health and
vitality.
Setting the benchmark as the gold standard in scientific rigor
and quality in the dietary supplement space, ChromaDex is the
innovator behind its clinically proven flagship ingredient, Niagen®
(patented nicotinamide riboside, or NR). Clinically proven to
increase NAD+ levels, Niagen is the most efficient and
superior-quality NAD+ booster helping people transform the way they
age.
Food-grade Niagen is available in the consumer dietary
supplement Tru Niagen®, the number one healthy-aging oral NAD+
supplement in the United States*, and through partnerships with
global retailers and distributors. Pharmaceutical-grade Niagen will
soon be available through FDA-registered 503B outsourcing
facilities and will be administered at clinics pursuant to a valid
prescription.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $10.5 trillion in
assets are benchmarked against Russell's U.S. indexes. FTSE
Russell, a leading global index provider, administers these
indexes.
For more information on the Russell 2000® Index and the Russell
indexes reconstitution, please visit the Russell Reconstitution
Section on the FTSE Russell website. Learn more about ChromaDex by
visiting www.chromadex.com.
Forward Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to ChromaDex’s inclusion in
the Russell 2000® Index as part of the annual reconstitution of the
Russell stock indexes. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects," "anticipates," "intends," "estimates," "plans,"
"potential," "possible," "probable," "believes," "seeks," "may,"
"will," "should," "could" or the negative of such terms or other
similar expressions. Risks that contribute to the uncertain nature
of these forward-looking statements include the impact of the
COVID-19 pandemic on our business and the global economy; our
history of operating losses and need to obtain additional
financing; the growth and profitability of our product sales; our
ability to maintain sales, marketing and distribution capabilities;
changing consumer perceptions of our products; our reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with our business and financial
condition. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2023, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on
nicotinamide adenine dinucleotide (NAD+), with a focus on the
science of healthy aging. The ChromaDex team, comprised of
world-renowned scientists, works with independent investigators
from esteemed universities and research institutions around the
globe to uncover the full potential of NAD+. A vital coenzyme found
in every cell of the human body, NAD+ declines with age and
exposure to other everyday stressors. NAD+ depletion is a
contributor to age-related changes in health and vitality. Setting
the benchmark as the gold standard in scientific rigor and quality
in the dietary supplement space, ChromaDex is the innovator behind
its clinically proven flagship ingredient, Niagen® (patented
nicotinamide riboside, or NR). Clinically proven to increase NAD+
levels, Niagen is the most efficient and superior-quality NAD+
booster helping people transform the way they age.
Food-grade Niagen is manufactured by ChromaDex and is available
in the consumer dietary supplement Tru Niagen®, the number one
healthy-aging oral NAD+ supplement in the United States* (available
at www.truniagen.com). Pharmaceutical-grade Niagen will be
available through FDA-registered 503B outsourcing facilities and
will be administered at clinics pursuant to a valid prescription
(www.niagenplus.com).
ChromaDex’s robust patent portfolio protects NR and other NAD+
precursors. ChromaDex maintains a website at www.chromadex.com, to
which ChromaDex regularly publishes copies of its press releases,
news, and financial information.
*Based on the top-selling dietary supplement brands by revenue
per the largest U.S. e-commerce marketplace (as of
3/1/2023-2/29/2024).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240701261918/en/
ChromaDex Media Contact: Kendall Knysch, Senior Director
of Media Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: Ben Shamsian Lytham
Partners 646-829-9701 shamsian@lythampartners.com
Grafico Azioni ChromaDex (NASDAQ:CDXC)
Storico
Da Mar 2025 a Apr 2025
Grafico Azioni ChromaDex (NASDAQ:CDXC)
Storico
Da Apr 2024 a Apr 2025
